Phase 2 trials
Mid-sized trials in people have measured dose and effect. It is not a licensed medicine.
This page is a stub
The wiki has this compound's identity from the My-Pepts library, its standing, and what PubMed holds for it. The article, with its studies read and cited, is not written yet. Until it is, the counts below say how much research exists, not what it found.
How strong is the evidence
How far it has climbed
Every medicine climbs the same ladder. Most compounds never reach the top, and where one stands says how much its claims can carry.
- Licensed medicine
A regulator has reviewed the trials and licensed it for a named use.
- Phase 3
Large randomized trials, often thousands of people, against placebo or a standard treatment.
- Phase 2: Eloralintide
Mid-sized trials that measure dose against effect in people with the condition.
- Phase 1 and early human studies
First studies in people: safety, and how the body handles it.
- Cells and animals
Laboratory and animal work. An animal result is not a result in people.
- 10
- papers on PubMed
- 7
- of them in people
- 3
- randomized trials
- 6
- reviews
A count says how much has been published, not what it found. Counted on PubMed: 2026-11-16
Handling and reconstitution
From powder to a measured sample
The same four steps for any lyophilized vial. Laboratory handling, not use in a person.
1. Read the vial
The label gives the mass of peptide in the vial, in milligrams. That number is the start of every calculation.
2. Add the diluent
A measured volume of diluent goes in slowly, down the glass. Swirl gently; shaking can damage a peptide.
3. Work out the strength
Concentration is mass divided by volume: 10 mg in 2 mL is 5 mg per mL.
4. Measure the sample
Volume is the mass wanted divided by the concentration. On a U-100 syringe, 1 mL is 100 units.
The calculator below does the arithmetic and shows its working.
As powder
General practice for lyophilized peptides: keep the sealed vial frozen or refrigerated, dry and away from light, and follow the supplier's certificate of analysis.
In solution
Once in solution a peptide is kept refrigerated and used within the period the supplier states. A vial drawn from more than once needs a preserved diluent such as bacteriostatic water.
This is general practice for lyophilized peptides, not data on Eloralintide itself. The batch's certificate of analysis and the supplier's sheet are the facts to go by. More on storage
Reconstitution calculator
Opens on vial sizes common for research peptides. Change any number. How the arithmetic works
Draw to
10 units
0.1 mL on a U-100 syringe
- Concentration
- 2.5 mg/mL
- Each unit holds
- 25 mcg
- Samples in the vial
- 20
- Sample
- 250 mcg
5 mg in 2 mL is 2.5 mg/mL. 250 mcg of that is 0.1 mL, which reads as 10 units. This is arithmetic for a vial of Eloralintide; no amount here is a recommendation.
Eloralintide: on PubMed
What PubMed held for Eloralintide on November 16, 2026. A count says how much a compound has been studied, not what the studies found: how to read these numbers.
- 10
- papers
- 7
- in humans
- 3
- clinical trials
- 3
- randomized trials
Most relevant on PubMed
Listed by PubMed's own relevance ranking, trials and reviews first. The wiki has not read these into the article unless they are also among its sources.
- Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Randomized trialBriere DA, Qu H, Lansu K, et al. Molecular metabolism, 2025. PMID 41109426
- Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentre, double-blind, randomised, placebo-controlled trial
Randomized trialBillings LK, Hsia S, Bays H, et al. Lancet (London, England), 2025. PMID 41207310
- Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept
Randomized trialBhattachar S, Tham LS, Tidemann-Miller B, et al. Diabetes, obesity & metabolism, 2026. PMID 41559929
- Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A Network Meta-Analysis
ReviewKamrul-Hasan ABM, Khalil I, Mahajan K, et al. Endocrinology, diabetes & metabolism, 2026. PMID 42175595
- Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes
ReviewBailey CJ, Flatt PR, Conlon JM Peptides, 2026. PMID 41747885
- New Amylin-Based Agonists for the Treatment of Obesity and Type 2 Diabetes Mellitus
ReviewPanou T, Gouveri E, Popovic DS, et al. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. PMID 42803913
- Amylin Analogs: The Next Major Class of Weight Loss Therapy: A Review of Experimental Data and Early-Phase Clinical Trials
ReviewAlhazmi A, le Roux CW Diabetes, obesity & metabolism, 2026. PMID 42452898
- Beyond GLP-1: Amylin-based pharmacotherapy and the search for better-tolerated weight-loss drugs
ReviewFischer SL, Borner T Pharmacological research, 2026. PMID 42586227
Search used: ("Eloralintide"[tiab]). Run it on PubMed
Research links
- PubMed (opens in a new tab)Every indexed paper, newest first
- ClinicalTrials.gov (opens in a new tab)Registered trials and their status
- Europe PMC (opens in a new tab)Full text where it is open access
- Google Scholar (opens in a new tab)Papers, preprints and who cites them
- PubChem (opens in a new tab)Structure, identifiers and properties
- YouTube (opens in a new tab)Talks and lectures. Check who is speaking
These open a search for Eloralintide on each site. The wiki has not reviewed what they return: a video or a preprint is not a peer-reviewed result, and none of it is medical advice.